The latest Drug Administration Law amendments introduce welcome changes such as relaxed permit requirements and free prices. Pharmaceutical companies should keep abreast of the drug pricing reform, and track review and approval changes in the pipeline
The latest Drug Administration Law amendments introduce welcome changes such as relaxed permit requirements and free prices. Pharmaceutical companies should keep abreast of the drug pricing reform, and track review and approval changes in the pipeline
China's efforts to crack down on misleading, fraudulent claims forces an industry rethink as they overturn the effects of years of aggressive marketing. The new law regulates content, target audiences and specific industries like tobacco and healthcare, and will increase compliance costs for consumer-oriented businesses
The SAIC's new Provisions emphasise the interplay between IP and competition, specifically agreements, restrictive acts, patent pools and standard essential patents. Businesses should learn from the Qualcomm and Huawei v InterDigital cases and be wary of large revenue-based penalties
Yaodong Chen, APAC director of IP for Akzo Nobel, shares with China Law & Practice his thoughts on trade secret protection in China, why inventor remuneration is burdensome for businesses and the importance of building up IP assets
The millions in fines imposed on polluters and arrests of executives indicate the seriousness of China's efforts to enforce the year-old revised Environmental Protection Law. This feature lists some of the things multinationals can do to stay out of trouble
The millions in fines imposed on polluters and arrests of executives indicate the seriousness of China's efforts to enforce the year-old revised Environmental Protection Law. This feature lists some of the things multinationals can do to stay out of trouble
Peter Fuhrman, CEO of China First Capital, explains how the country's private equity market has struggled with profit returns and the importance of diversified exit strategies. He also predicts the rise of new funds to execute high-yield deals
The Beijing IP Court's decision to reject Trunkbow's “Weixin” trademark - even though it was filed before Tencent's - has caused controversy, but one thing is clear: judges are increasingly taking into account consumers' welfare and not necessarily going by the book
The Beijing IP Court's decision to reject Trunkbow's “Weixin” trademark - even though it was filed before Tencent's - has caused controversy, but one thing is clear: judges are increasingly taking into account consumers' welfare and not necessarily going by the book